InvestorsHub Logo
Followers 24
Posts 1202
Boards Moderated 0
Alias Born 01/27/2021

Re: sstyles post# 354541

Wednesday, 09/15/2021 1:03:32 PM

Wednesday, September 15, 2021 1:03:32 PM

Post# of 429456
I haven't read all the court papers in the infringement case, but it might be very different from the GSK-Teva case as far as the likely potential exposure Hikma would have to damages.

I think part of Amarin's contention is that Hikma induced infringement with its initial press releases and such. But then Hikma supposedly changed its public materials or withdrew some of its releases. Of course that's exactly what a guilty entity would do! I don't know if that would allow a jury to conclude that every dollar Hikma made since it was permitted to sell generic Vascepa is subject to a jury award of triple damages or just money made during a narrower period. I'm not a lawyer.

And Dr. Reddys hasn't been sued so far.

The actions Hikma has taken in the market for Vascepa does not show any hesitancy since the Federal Circuit ruling so clearly the company does not believe its exposure warrants shutting down sales.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News